Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: A comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells

Oncology Reports

Volumn 16, Issue 6, 2006, Pages 1317-1324

  Yasuda, Takashi ^a   Kamigaki, Takashi ^a   Nakamura, Tetsu ^a   Imanishi, Tatsuya ^a   Hayashi, Shun ^a   Kawasaki, Kentaro ^a   Takase, Shiro ^a   Ajiki, Tetsuo ^a   Kuroda, Yoshikazu ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Antigen loading; Cytotoxic T lymphocytes; Dendritic cell based immunotherapy; Dendritic cell tumor cell hybrids; Tumor immunity

Indexed keywords

CANCER VACCINE; CELL EXTRACT; TUMOR ANTIGEN;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL FUSION; COLON TUMOR; COMPARATIVE STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HYBRID CELL; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOUSE; NECROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; CANCER VACCINES; CELL EXTRACTS; CELL FUSION; COLONIC NEOPLASMS; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HYBRID CELLS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; NECROSIS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34250180058     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.6.1317     Document Type: Article

References (32)

1. Gallucci S, Lolkema M and Matzinger P: Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5: 1249-1255, 1999. (Pubitemid 29535601)
2. Boczkowski D, Nair SK, Snyder D and Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184: 465-472, 1996. (Pubitemid 26324100)
3. Fields RC, Shimizu K and Mule JJ: Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95: 9482-9487, 1998. (Pubitemid 28506257)
4. Gong J, Chen DS, Kashiwaba M and Kufe D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3: 558-561, 1997. (Pubitemid 27198656)
5. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB and Lotze MT: Bone-marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1: 1297-1302, 1995.
6. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D and Taidi B: Vaccination of patients with B-cell lymphoma using autologus antigen-pulsed dendritic cells. Nat Med 2: 52-58, 1996. (Pubitemid 26028073)
7. Nestle FO, Alijagic S, Gilliet M, Sun YS, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998. (Pubitemid 28144092)
8. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA and Ragde H: Infusion of dendritic cells pulsed with HLA-A2 specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38: 71-78, 1999.
9. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A and Brossart P: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6: 332-336, 2000. (Pubitemid 30148627)
10. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski K, Bhardwaj N, Piniero L, Steinman R and Fay J: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61: 6451-6458, 2001. (Pubitemid 32783251)
11. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L and Brugger W: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96: 3102-3108, 2000.
12. Pecher G, Spahn G, Schirrmann T, Kulbe H, Ziegner M, Schenk JA and Sandig V: Mucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirus. Anticancer Res 21: 2591-2596, 2001. (Pubitemid 33054429)
13. Chaput N, Schartz NE, Andre F, Taieb J, Novault S, Bonnaventure P, Aubert N, Bemard J, Lemonnier F, Merad M, Adema G, Adams M, Ferrantini M, Carpentier AF, Escudier B, Tursz T, Angevin E and Zitvogel L: Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 172: 2137-2146, 2004. (Pubitemid 38182359)
14. Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E, Blanck JP, Johnston DA, Palucka AK and Fay J: Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with Type I interferon. J Immunother Emphasis Tumor Immunol 28: 505-516, 2005. (Pubitemid 41232572)
15. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD and Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186: 1177-1182, 1997. (Pubitemid 27441162)
16. Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, Rimoldi D, Cerottini J, Banchereaux J and Palucka AK: Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 192: 1535-1544, 2000.
17. Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J and Palucka KA: Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 165: 3797-3803, 2000. (Pubitemid 32057286)
18. Gong J, Nikrui N, Chen DS, Koido S, Wu ZK, Tanaka Y, Cannistra S, Avigan D and Kufe D: Fusions of human ovarian carcinoma cells with autologus or allogenic dendritic cells induce antitumor immunity. J Immunol 165: 1705-1711, 2000. (Pubitemid 30604610)
19. Galea-Lauri J, Wells JW, Darling D, Harrison P and Farzaneh F: Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother 53: 963-977, 2004. (Pubitemid 39371741)
20. Shimizu K, Kuriyama H, Kjaergaard J, Lee W, Tanaka H and Shu S: Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother Emphasis Tumor Immunol 27: 265-272, 2004. (Pubitemid 38833322)
21. Galea-Lauri J, Darling D, Mufti G, Harrison P and Farzaneh F: Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 51: 299-310, 2002. (Pubitemid 34743982)
22. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sharav T, Sparbier K, Sterry W and Walden P: Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine 23: 2367-2373, 2005. (Pubitemid 40341486)
23. Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, Eis-Hubinber AM, Muller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T and Schmidt-Wolf IG: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14: 483-494, 2003. (Pubitemid 36403540)
24. Lutz MB, Kukutsch N, Ogilvie ALJ, Rossner S, Koch F, Romani N and Schuler G: An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77-92, 1999. (Pubitemid 29096240)
25. Harris N, Campbell C, Le Gros G and Ronchese F: Blockade of CD28/B7 co-stimulation by mCTLA4-Hgamma1 inhibits antigen-induced lung eosinophilia but not Th2 cell development or recruitment in the lung. Eur J Immunol 27: 155-161, 1997. (Pubitemid 27046072)
26. Wang J, Saffold S, Cao X, Krauss J and Chen W: Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 161: 5516-5524, 1998. (Pubitemid 28519115)
27. Ferlazzo G, Semino C, Spaggiari GM, Meta M, Mingari MC and Melioli G: Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates. Int Immunol 12: 1741-1747, 2000. (Pubitemid 32007728)
28. Kotera Y, Shimizu K and Mule JJ: Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 61: 8105-8109, 2001. (Pubitemid 33091598)
29. Kao JY, Zhang M, Chen CM and Chen JJ: Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol Lett 101: 154-159, 2005. (Pubitemid 41368073)
30. Ferlazzo G, Pack M, Thomas D, Paludan C, Schmid D, Strowig T, Bougras G, Muller WA, Moretta L and Munz C: Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci USA 101: 16606-16611, 2004. (Pubitemid 39557760)
31. Ruckert R, Brandt K, Bulanova E, Mirghomizadeh F, Paus R and Bulfone-Paus S: Dendritic cell-derived IL-15 controls the induction of CD8 T cell immune responses. Eur J Immunol 33: 3493-3503, 2003. (Pubitemid 37541128)
32. + T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines. Vaccine 21: 869-876, 2003.